Recent Updates
Recently added Catalysts
QGEN Positive Sentiment

QIAGEN Reports Full Q3 2026 Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QIAGEN N.V. reported its Q3 2026 results, revealing net sales of $548 million, a 3% increase from Q3 2025. The growth rate matched the constant exchange rates (CER) increase of 3%, surpassing the company's outlook of 1-2% growth. Adjusted diluted earnings per share also exceeded expectations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net sales increased 3% to $548 million.
  • Adjusted diluted EPS exceeded expectations.
  • Sales growth surpassed the outlook of 1-2%.

Full Press Release Details

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced full results for the third quarter of 2026, with net sales and adjusted diluted earnings per share (EPS) ahead of the outlook. In line with preliminary results, Q3 2026 sales rose 3% to $548 million compared with Q3 2025, also increasing 3% at constant exchange rates (CER) and exceeding the outlook for about 1-2% CER growth. Consumables and related revenues rose 3% CER

Frequently Asked Questions

What were QIAGEN's net sales for Q3 2026?

QIAGEN's net sales for Q3 2026 were $548 million.

How much did sales increase compared to Q3 2025?

Sales increased by 3% compared to Q3 2025.

Did QIAGEN meet its sales growth outlook?

Yes, QIAGEN exceeded its sales growth outlook of 1-2%.

What was the adjusted diluted EPS for Q3 2026?

The adjusted diluted EPS for Q3 2026 was ahead of expectations.

ShareAdd on Google
Tags: QGEN QIAGEN Q3 2026 net sales earnings per share financial results
Last updated: Nov 4, 2026